Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.
In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.
Canaccord Genuity began coverage of Castle Biosciences with a Buy rating and a $26 price target, while SVB Leerink assigned an Outperform rating and a $28 price target.
The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.
The company said it is on track to complete a clinical validation by the end of next year, after which it would launch its assay for clinical use.
The clinic will offer comprehensive DNA sequencing, interpretation, and reporting of disease-associated genes for healthy adults and their children.
Researchers have launched a startup called Fluxus to commercialize a platform based on the optofluidic chip for molecular analysis.
Beyond its HostDx Sepsis test, the firm is working on a test to detect and differentiate bacterial from viral infections in patients presenting with fever.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.